Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US
Lauren A. Eberly, Lin Yang, Utibe R. Essien, et al.
JAMA Health Forum (2021) Vol. 2, Iss. 12, pp. e214182-e214182
Open Access | Times Cited: 142

Showing 1-25 of 142 citing articles:

Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association
Chiadi E. Ndumele, Janani Rangaswami, Sheryl L. Chow, et al.
Circulation (2023) Vol. 148, Iss. 20, pp. 1606-1635
Open Access | Times Cited: 397
Association of Race and Ethnicity With Prescription of SGLT2 Inhibitors and GLP1 Receptor Agonists Among Patients With Type 2 Diabetes in the Veterans Health Administration System
Julio A. Lamprea‐Montealegre, Erin Madden, Sri Lekha Tummalapalli, et al.
JAMA (2022) Vol. 328, Iss. 9, pp. 861-861
Open Access | Times Cited: 78
Prevalence and Overlap of Cardiac, Renal, and Metabolic Conditions in US Adults, 1999-2020
John W. Ostrominski, Suzanne V. Arnold, Javed Butler, et al.
JAMA Cardiology (2023) Vol. 8, Iss. 11, pp. 1050-1050
Open Access | Times Cited: 63
Disparities in diabetes prevalence and management by race and ethnicity in the USA: defining a path forward
Saria Hassan, Unjali P. Gujral, Rakale C. Quarells, et al.
The Lancet Diabetes & Endocrinology (2023) Vol. 11, Iss. 7, pp. 509-524
Closed Access | Times Cited: 51
Role of Glucagon‐Like Peptide‐1 Receptor Agonists in Achieving Weight Loss and Improving Cardiovascular Outcomes in People With Overweight and Obesity
Erin D. Michos, Francisco López-Jiménez, Martha Gulati
Journal of the American Heart Association (2023) Vol. 12, Iss. 11
Open Access | Times Cited: 43
GLP-1 Agonists for Obesity—A New Recipe for Success?
Dariush Mozaffarian
JAMA (2024) Vol. 331, Iss. 12, pp. 1007-1007
Closed Access | Times Cited: 28
Disproportionality Analysis From World Health Organization Data on Semaglutide, Liraglutide, and Suicidality
Georgios Schoretsanitis, Stefan Weiler, Corrado Barbui, et al.
JAMA Network Open (2024) Vol. 7, Iss. 8, pp. e2423385-e2423385
Open Access | Times Cited: 25
Fair Allocation of GLP-1 and Dual GLP-1–GIP Receptor Agonists
Ezekiel J. Emanuel, Johan Dellgren, Matthew S. McCoy, et al.
New England Journal of Medicine (2024) Vol. 390, Iss. 20, pp. 1839-1842
Closed Access | Times Cited: 20
Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021
Jessica A. Kerr, George Patton, Karly Cini, et al.
The Lancet (2025) Vol. 405, Iss. 10481, pp. 785-812
Open Access | Times Cited: 8
The Effect of Semaglutide and GLP-1 RAs on Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy
Nadia J. Abbass, Raya Nahlawi, Jacqueline K. Shaia, et al.
American Journal of Ophthalmology (2025)
Open Access | Times Cited: 3
Socioeconomic aspects of incretin-based therapy
Thomas Karagiannis, Eleni Bekiari, Απόστολος Τσάπας
Diabetologia (2023) Vol. 66, Iss. 10, pp. 1859-1868
Open Access | Times Cited: 30
Association of Prescription Co-payment With Adherence to Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Therapies in Patients With Heart Failure and Diabetes
Utibe R. Essien, Balvindar Singh, Gretchen Swabe, et al.
JAMA Network Open (2023) Vol. 6, Iss. 6, pp. e2316290-e2316290
Open Access | Times Cited: 24
GLP-1 receptor agonists and diabetic retinopathy: A meta-analysis of randomized clinical trials
Ishani Kapoor, Swara M. Sarvepalli, David A. D’Alessio, et al.
Survey of Ophthalmology (2023) Vol. 68, Iss. 6, pp. 1071-1083
Closed Access | Times Cited: 24
Race and ethnicity and pharmacy dispensing of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
Luis A. Rodríguez, Holly Finertie, Romain Neugebauer, et al.
The Lancet Regional Health - Americas (2024) Vol. 34, pp. 100759-100759
Open Access | Times Cited: 9
Understanding the bidirectional association between obesity and risk of psychological distress and depression in young adults in the US: available evidence, knowledge gaps, and future directions
Michael Friedman, Ryan Chang, Zahir Amin, et al.
Frontiers in Psychiatry (2025) Vol. 15
Open Access | Times Cited: 1
Learning from the roundtable on obesity solutions experiences: A 10-year anniversary point of view
Nicolaas P. Pronk, William H. Dietz, Christina D. Economos, et al.
Progress in Cardiovascular Diseases (2025)
Closed Access | Times Cited: 1
Randomized Evaluation of a Remote Management Program to Improve Guideline-Directed Medical Therapy: The DRIVE Trial
Alexander Blood, Lee‐Shing Chang, Shahzad Hassan, et al.
Circulation (2024) Vol. 149, Iss. 23, pp. 1802-1811
Closed Access | Times Cited: 8
Comparative Effects of GLP-1 Receptor Agonists and Metformin on Glaucoma Risk in Type 2 Diabetes Patients
Jawad Muayad, Asad Loya, Zain Hussain, et al.
Ophthalmology (2024)
Closed Access | Times Cited: 8
Estimating the lives that could be saved by expanded access to weight-loss drugs
Abhishek Pandey, Ye Yang, Chad R. Wells, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 43
Open Access | Times Cited: 8
Sociodemographic disparities in GLP-1RA and SGLT2i use among US adults with type 2 diabetes: NHANES 2005-March 2020
Benjamin G Mittman, Phuc Le, Julia Y. Payne, et al.
Current Medical Research and Opinion (2024) Vol. 40, Iss. 3, pp. 377-383
Closed Access | Times Cited: 7
Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Exploring Their Impact on Diabetes, Obesity, and Cardiovascular Health Through a Comprehensive Literature Review
Khalid M Hamed, Mohammed N Alosaimi, Bashaer A Ali, et al.
Cureus (2024)
Open Access | Times Cited: 7
1. Improving Care and Promoting Health in Populations: Standards of Care in Diabetes—2025
Nuha A. ElSayed, Rozalina G. McCoy, Grazia Aleppo, et al.
Diabetes Care (2024) Vol. 48, Iss. Supplement_1, pp. S14-S26
Closed Access | Times Cited: 7
Geographic variation and racial disparities in adoption of newer glucose-lowering drugs with cardiovascular benefits among US Medicare beneficiaries with type 2 diabetes
Wei‐Han Chen, Yujia Li, Lanting Yang, et al.
PLoS ONE (2024) Vol. 19, Iss. 1, pp. e0297208-e0297208
Open Access | Times Cited: 6
Major adverse cardiovascular events among patients with type-2 diabetes, a nationwide cohort study comparing primary metabolic and bariatric surgery to GLP-1 receptor agonist treatment
Erik Stenberg, Erik Näslund
International Journal of Obesity (2023) Vol. 47, Iss. 4, pp. 251-256
Open Access | Times Cited: 16
Social determinants of health, health disparities, and adiposity
Andrew S. Baez, Lola R. Ortiz-Whittingham, Hannatu Tarfa, et al.
Progress in Cardiovascular Diseases (2023) Vol. 78, pp. 17-26
Closed Access | Times Cited: 16
Page 1 - Next Page

Scroll to top